RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study
Background: Masseter hypertrophy can be ameliorated by botulinum toxin. Objective: To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy. Methods: Sixteen women with bilateral masseter hypertrophy received single inj...
Gespeichert in:
| Veröffentlicht in: | Dermatology (Basel) 2013-01, Vol.226 (3), p.227-232 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 232 |
|---|---|
| container_issue | 3 |
| container_start_page | 227 |
| container_title | Dermatology (Basel) |
| container_volume | 226 |
| creator | Lee, Dong Hun Jin, Seon-Pil Cho, Soyun Feneran, Ashley Youn, Choon Shik Won, Chong Hyun Park, Gyeong-Hun Kim, Byung Wook An, Jeesoo Chang, Sung Eun Lee, Mi Woo |
| description | Background: Masseter hypertrophy can be ameliorated by botulinum toxin. Objective: To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy. Methods: Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study. Results: Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.6 and 14.2%, respectively). At week 24, only masseters treated with BTX-A maintained a significant volume reduction. Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements. Conclusion: Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A. |
| doi_str_mv | 10.1159/000349984 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_karge</sourceid><recordid>TN_cdi_proquest_journals_1428558245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3057614851</sourcerecordid><originalsourceid>FETCH-LOGICAL-c474t-3f1ee515fd9c176a9ac94802395028d5b44e1f252345ce2f8fb6c387254a2f3b3</originalsourceid><addsrcrecordid>eNpd0ctO3DAUBmCroiqUdtF9hSyxKYuArxOb3UChIIGQuIhl5CTHJZDEwRfE9BH61DWa6SxY2ZI__7LPj9A3SvYplfqAEMKF1kp8QFtUMFpoxdlG3hOqCjWbyU30OYTHzJgq9Se0yXhZCsLJFvp73Q2mdjH13ZiG6F678Qi_gA8p4Kvx3ckcdyOOD4BvPZg4wBixs_jShAARPD5bTOCjd9PD4hDPMRPFPcAT_ulS3UNxlHNafG3G1g3dH2jxzdR3sTg1DeCbmNrFF_TRmj7A19W6je5OT26Pz4qLq1_nx_OLohGliAW3FEBSaVvd0HJmtGm0UIRxLfP3WlkLAdQyybiQDTCrbD1ruCqZFIZZXvNt9GOZO3n3nCDEauhCA31vRnApVHmCgjOhpMh09x19dMmP-XVvSkmpmJBZ7S1V410IHmw1-TxVv6goqd4KqtYFZbuzSkz1AO1a_m8kg-9L8GT8b_BrsLr_D1YelD4</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1428558245</pqid></control><display><type>article</type><title>RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study</title><source>MEDLINE</source><source>Karger Journals Complete</source><creator>Lee, Dong Hun ; Jin, Seon-Pil ; Cho, Soyun ; Feneran, Ashley ; Youn, Choon Shik ; Won, Chong Hyun ; Park, Gyeong-Hun ; Kim, Byung Wook ; An, Jeesoo ; Chang, Sung Eun ; Lee, Mi Woo</creator><creatorcontrib>Lee, Dong Hun ; Jin, Seon-Pil ; Cho, Soyun ; Feneran, Ashley ; Youn, Choon Shik ; Won, Chong Hyun ; Park, Gyeong-Hun ; Kim, Byung Wook ; An, Jeesoo ; Chang, Sung Eun ; Lee, Mi Woo</creatorcontrib><description>Background: Masseter hypertrophy can be ameliorated by botulinum toxin. Objective: To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy. Methods: Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study. Results: Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.6 and 14.2%, respectively). At week 24, only masseters treated with BTX-A maintained a significant volume reduction. Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements. Conclusion: Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A.</description><identifier>ISSN: 1018-8665</identifier><identifier>EISSN: 1421-9832</identifier><identifier>DOI: 10.1159/000349984</identifier><identifier>PMID: 23774030</identifier><language>eng</language><publisher>Basel, Switzerland: S. Karger AG</publisher><subject>Adult ; Botulinum Toxins - adverse effects ; Botulinum Toxins - therapeutic use ; Botulinum Toxins, Type A - adverse effects ; Botulinum Toxins, Type A - therapeutic use ; Comparative studies ; Cosmetic Techniques ; Double-Blind Method ; Drug therapy ; Female ; Humans ; Hypertrophy - diagnostic imaging ; Hypertrophy - drug therapy ; Masseter Muscle - abnormalities ; Masseter Muscle - diagnostic imaging ; Mouth ; Muscular system ; Neuromuscular Agents - adverse effects ; Neuromuscular Agents - therapeutic use ; Original Paper ; Patient Satisfaction ; Tomography, X-Ray Computed ; Young Adult</subject><ispartof>Dermatology (Basel), 2013-01, Vol.226 (3), p.227-232</ispartof><rights>2013 S. Karger AG, Basel</rights><rights>Copyright © 2013 S. Karger AG, Basel.</rights><rights>Copyright (c) 2013 S. Karger AG, Basel</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c474t-3f1ee515fd9c176a9ac94802395028d5b44e1f252345ce2f8fb6c387254a2f3b3</citedby><cites>FETCH-LOGICAL-c474t-3f1ee515fd9c176a9ac94802395028d5b44e1f252345ce2f8fb6c387254a2f3b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,2429,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23774030$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lee, Dong Hun</creatorcontrib><creatorcontrib>Jin, Seon-Pil</creatorcontrib><creatorcontrib>Cho, Soyun</creatorcontrib><creatorcontrib>Feneran, Ashley</creatorcontrib><creatorcontrib>Youn, Choon Shik</creatorcontrib><creatorcontrib>Won, Chong Hyun</creatorcontrib><creatorcontrib>Park, Gyeong-Hun</creatorcontrib><creatorcontrib>Kim, Byung Wook</creatorcontrib><creatorcontrib>An, Jeesoo</creatorcontrib><creatorcontrib>Chang, Sung Eun</creatorcontrib><creatorcontrib>Lee, Mi Woo</creatorcontrib><title>RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study</title><title>Dermatology (Basel)</title><addtitle>Dermatology</addtitle><description>Background: Masseter hypertrophy can be ameliorated by botulinum toxin. Objective: To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy. Methods: Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study. Results: Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.6 and 14.2%, respectively). At week 24, only masseters treated with BTX-A maintained a significant volume reduction. Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements. Conclusion: Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A.</description><subject>Adult</subject><subject>Botulinum Toxins - adverse effects</subject><subject>Botulinum Toxins - therapeutic use</subject><subject>Botulinum Toxins, Type A - adverse effects</subject><subject>Botulinum Toxins, Type A - therapeutic use</subject><subject>Comparative studies</subject><subject>Cosmetic Techniques</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Female</subject><subject>Humans</subject><subject>Hypertrophy - diagnostic imaging</subject><subject>Hypertrophy - drug therapy</subject><subject>Masseter Muscle - abnormalities</subject><subject>Masseter Muscle - diagnostic imaging</subject><subject>Mouth</subject><subject>Muscular system</subject><subject>Neuromuscular Agents - adverse effects</subject><subject>Neuromuscular Agents - therapeutic use</subject><subject>Original Paper</subject><subject>Patient Satisfaction</subject><subject>Tomography, X-Ray Computed</subject><subject>Young Adult</subject><issn>1018-8665</issn><issn>1421-9832</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNpd0ctO3DAUBmCroiqUdtF9hSyxKYuArxOb3UChIIGQuIhl5CTHJZDEwRfE9BH61DWa6SxY2ZI__7LPj9A3SvYplfqAEMKF1kp8QFtUMFpoxdlG3hOqCjWbyU30OYTHzJgq9Se0yXhZCsLJFvp73Q2mdjH13ZiG6F678Qi_gA8p4Kvx3ckcdyOOD4BvPZg4wBixs_jShAARPD5bTOCjd9PD4hDPMRPFPcAT_ulS3UNxlHNafG3G1g3dH2jxzdR3sTg1DeCbmNrFF_TRmj7A19W6je5OT26Pz4qLq1_nx_OLohGliAW3FEBSaVvd0HJmtGm0UIRxLfP3WlkLAdQyybiQDTCrbD1ruCqZFIZZXvNt9GOZO3n3nCDEauhCA31vRnApVHmCgjOhpMh09x19dMmP-XVvSkmpmJBZ7S1V410IHmw1-TxVv6goqd4KqtYFZbuzSkz1AO1a_m8kg-9L8GT8b_BrsLr_D1YelD4</recordid><startdate>20130101</startdate><enddate>20130101</enddate><creator>Lee, Dong Hun</creator><creator>Jin, Seon-Pil</creator><creator>Cho, Soyun</creator><creator>Feneran, Ashley</creator><creator>Youn, Choon Shik</creator><creator>Won, Chong Hyun</creator><creator>Park, Gyeong-Hun</creator><creator>Kim, Byung Wook</creator><creator>An, Jeesoo</creator><creator>Chang, Sung Eun</creator><creator>Lee, Mi Woo</creator><general>S. Karger AG</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7U7</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope></search><sort><creationdate>20130101</creationdate><title>RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study</title><author>Lee, Dong Hun ; Jin, Seon-Pil ; Cho, Soyun ; Feneran, Ashley ; Youn, Choon Shik ; Won, Chong Hyun ; Park, Gyeong-Hun ; Kim, Byung Wook ; An, Jeesoo ; Chang, Sung Eun ; Lee, Mi Woo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c474t-3f1ee515fd9c176a9ac94802395028d5b44e1f252345ce2f8fb6c387254a2f3b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adult</topic><topic>Botulinum Toxins - adverse effects</topic><topic>Botulinum Toxins - therapeutic use</topic><topic>Botulinum Toxins, Type A - adverse effects</topic><topic>Botulinum Toxins, Type A - therapeutic use</topic><topic>Comparative studies</topic><topic>Cosmetic Techniques</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Female</topic><topic>Humans</topic><topic>Hypertrophy - diagnostic imaging</topic><topic>Hypertrophy - drug therapy</topic><topic>Masseter Muscle - abnormalities</topic><topic>Masseter Muscle - diagnostic imaging</topic><topic>Mouth</topic><topic>Muscular system</topic><topic>Neuromuscular Agents - adverse effects</topic><topic>Neuromuscular Agents - therapeutic use</topic><topic>Original Paper</topic><topic>Patient Satisfaction</topic><topic>Tomography, X-Ray Computed</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lee, Dong Hun</creatorcontrib><creatorcontrib>Jin, Seon-Pil</creatorcontrib><creatorcontrib>Cho, Soyun</creatorcontrib><creatorcontrib>Feneran, Ashley</creatorcontrib><creatorcontrib>Youn, Choon Shik</creatorcontrib><creatorcontrib>Won, Chong Hyun</creatorcontrib><creatorcontrib>Park, Gyeong-Hun</creatorcontrib><creatorcontrib>Kim, Byung Wook</creatorcontrib><creatorcontrib>An, Jeesoo</creatorcontrib><creatorcontrib>Chang, Sung Eun</creatorcontrib><creatorcontrib>Lee, Mi Woo</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Toxicology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Dermatology (Basel)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lee, Dong Hun</au><au>Jin, Seon-Pil</au><au>Cho, Soyun</au><au>Feneran, Ashley</au><au>Youn, Choon Shik</au><au>Won, Chong Hyun</au><au>Park, Gyeong-Hun</au><au>Kim, Byung Wook</au><au>An, Jeesoo</au><au>Chang, Sung Eun</au><au>Lee, Mi Woo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study</atitle><jtitle>Dermatology (Basel)</jtitle><addtitle>Dermatology</addtitle><date>2013-01-01</date><risdate>2013</risdate><volume>226</volume><issue>3</issue><spage>227</spage><epage>232</epage><pages>227-232</pages><issn>1018-8665</issn><eissn>1421-9832</eissn><abstract>Background: Masseter hypertrophy can be ameliorated by botulinum toxin. Objective: To compare the efficacy and safety of RimabotulinumtoxinB (BTX-B) and OnabotulinumtoxinA (BTX-A) in the treatment of masseter hypertrophy. Methods: Sixteen women with bilateral masseter hypertrophy received single injections of BTX-A or BTX-B at a dose ratio of 1:50 or 1:70 in a 24-week double-blind randomized split-face study. Results: Both BTX-A and BTX-B produced significant improvements in masseter hypertrophy. The maximum volume reduction, as determined by computed tomography scanning, at week 12 was comparable between BTX-A and BTX-B at a dose ratio of 1:70 (15.6 and 14.2%, respectively). At week 24, only masseters treated with BTX-A maintained a significant volume reduction. Investigator ratings and patient satisfaction scores paralleled objective computed tomography measurements. Conclusion: Both BTX-A and BTX-B are effective in the treatment of masseter hypertrophy. BTX-B, at a dose ratio of 1:70, has a comparable efficacy but a shorter duration of action than BTX-A.</abstract><cop>Basel, Switzerland</cop><pub>S. Karger AG</pub><pmid>23774030</pmid><doi>10.1159/000349984</doi><tpages>6</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1018-8665 |
| ispartof | Dermatology (Basel), 2013-01, Vol.226 (3), p.227-232 |
| issn | 1018-8665 1421-9832 |
| language | eng |
| recordid | cdi_proquest_journals_1428558245 |
| source | MEDLINE; Karger Journals Complete |
| subjects | Adult Botulinum Toxins - adverse effects Botulinum Toxins - therapeutic use Botulinum Toxins, Type A - adverse effects Botulinum Toxins, Type A - therapeutic use Comparative studies Cosmetic Techniques Double-Blind Method Drug therapy Female Humans Hypertrophy - diagnostic imaging Hypertrophy - drug therapy Masseter Muscle - abnormalities Masseter Muscle - diagnostic imaging Mouth Muscular system Neuromuscular Agents - adverse effects Neuromuscular Agents - therapeutic use Original Paper Patient Satisfaction Tomography, X-Ray Computed Young Adult |
| title | RimabotulinumtoxinB versus OnabotulinumtoxinA in the Treatment of Masseter Hypertrophy: A 24-Week Double-Blind Randomized Split-Face Study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-03T20%3A53%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_karge&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=RimabotulinumtoxinB%20versus%20OnabotulinumtoxinA%20in%20the%20Treatment%20of%20Masseter%20Hypertrophy:%20A%2024-Week%20Double-Blind%20Randomized%20Split-Face%20Study&rft.jtitle=Dermatology%20(Basel)&rft.au=Lee,%20Dong%20Hun&rft.date=2013-01-01&rft.volume=226&rft.issue=3&rft.spage=227&rft.epage=232&rft.pages=227-232&rft.issn=1018-8665&rft.eissn=1421-9832&rft_id=info:doi/10.1159/000349984&rft_dat=%3Cproquest_karge%3E3057614851%3C/proquest_karge%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1428558245&rft_id=info:pmid/23774030&rfr_iscdi=true |